Table 3

Reported presence of a data monitoring committee stratified by trial characteristics

Trial characteristicNData monitoring committee, N (%)P value
Reported
55 (18)
Not reported
245 (82)
Number of centres
 Single centre13914 (10)125 (90)<0.001
 Multicentre13241 (31)91 (69)
 Unclear290 (0)29 (100)
Number of nations
 Single nation28148 (17)233 (83)0.06
 Multinational197 (37)12 (63)
Sample size
 N randomised, median (range)300224 (10–60480)91 (10–9528)<0.001
Nature of the intervention
 Drug8527 (32)58 (68)0.001
 Vaccine145 (36)9 (64)
 Rehabilitation or psychosocial301 (3)29 (97)
 Prevention or screening143 (21)11 (79)
 Surgery or radiotherapy90 (0)9 (100)
 Communication, organisational or educational524 (8)48 (92)
 Alternative therapeutic144 (29)10 (71)
 Device292 (7)27 (93)
 Other*539 (17)44 (83)
Primary outcome type
 Behavioural464 (9)42 (91)0.16
 Biomarker5512 (22)43 (78)
 Pain143 (21)11 (79)
 Physiological13031 (24)99 (76)
 Psychological282 (7)26 (93)
 Techniques/training131 (8)12 (92)
 Quality of life50 (0)5 (100)
 Other92 (22)7 (78)
Industry or pharmaceutical funding
 Yes5016 (32)34 (68)0.009
 No25039 (16)211 (84)
  • *Included therapeutic nutritional interventions (eg, supplements, infant formula and probiotics), sensorimotor interventions, physical activity interventions and financial interventions.